Aelis Farma is a biotech company conducting research and development on innovative signaling specific drugs
Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 13, 2019 | Series Unknown | €11M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Aelis Innovation | — | Series Unknown |
fonds régionaux ACI | — | Series Unknown |
NACO | — | Series Unknown |
Inserm Transfert Initiative | — | Series Unknown |